Budipine

Research use only, not for human use.

Budipine is a low affinity N-methyl-D-aspartate receptor antagonistis an antiparkinsonian agent.

Budipine is a low affinity N-methyl-D-aspartate receptor antagonistis an antiparkinsonian agent.

——

Budipine (s.c., 30 μg/24 h, 11 days) is a substrate of P-glycoprotein (P-gp) and is actively transported out of the brain through the blood–brain barrier back into the blood plasma. Animal Model:Male abcblab(-/-) mice Male abcblab(-/-) mice (n=8, weight 29.0 g) and FVB/N wild-type mice (n =8, weight 28.0 g).Dosage:30 μg(Budipine is dissolved in 0.9% sodium chloride and 0.5% ethanol).Administration:subcutaneous injections, continuously delivered 30 μg over 24 h, 11 days Result:Increased the cerebrum concentration for 3.1 times high in knock-out mice after an 11-day continuous administration.Showed no significant differences in plasma, spleen, kidney and liver.

——

Others

Other Targets

N-methyl-D-aspartate

——

——

57982-78-2

293.45

C21H27N

>98% (HPLC)

In Vitro:?DMSO : 25 mg/mL (85.19 mM)

CC(C)(C)N1CCC(c2ccccc2)(c2ccccc2)CC1

——

(-20℃)

With Ice Pack

≥ 2 years